S C I E N T I F I C P R O G R A M |
||
*All sessions will be in Potsdam I, unless specified otherwise
|
||
Friday, February 4, 2011 |
||
8:00 |
16:00 |
Registration and Distribution of Materials |
9:00 |
10:30 |
SATELLITE SYMPOSIUM Sponsored by LEO PharmaVTE and pregnancy: what we know, what we need to know Chairs: Ian Greer, United Kingdom and Shannon Bates, Canada |
|
Welcome; Introduction to part 1 Ian Greer, UK and Shannon Bates, Canada Clinical outcomes with the LMWH, tinzaparin in pregnancy: an international Management of PE in pregnant patients; Florence Parent, France ACCP guidelines for pregnancy: challenges and controversies; Shannon Bates, Canada Coffee Break Registry data from Norway on the role of risk factors in deciding whether prophylaxis is necessary after C-section; Anne Flem Jacobsen, Norway Q & A session; Chairs and all speakers Introduction to part 2 – interactive session; Chairs Case 1: treatment; John Higgins, Ireland Case 2: prophylaxis; Thomas Bergholt, Denmark Summary; Chairs |
|
12:30 |
Lunch sponsored by LEO Pharma |
|
13:30 |
WHITH 2011 Opening Remarks Benjamin Brenner, Israel and Ian Greer, UK |
|
13:40-15:35 |
Session 1: CANCER AND THROMBOSIS IN WOMENChairmen: Anna Falanga, Italy Dominique Farge-Bancel, France |
|
|
13:40 |
Pathophysiology of Cancer and Thrombosis Anna Falanga, Italy |
14:05 |
Epidemiology of VTE in Women with Cancer Manuel Monreal, Spain |
|
14:30 |
Prevention of VTE in Women with Cancer Alexander Cohen, UK |
|
14:55 |
Treatment of VTE in Women with Cancer Rupert M. Bauersachs, Germany |
|
15:20 |
Selected Oral Abstracts (1a) Impact of common thrombophilias and JAK2 V617F on pregnancy outcomes in (1b) All trans-retinoic acid modulates the procoagulant activity of human breast cancer |
|
15:45-17:15 |
Session 2: PULMONARY EMBOLISMChairmen: Guy Meyer, France Catherine Nelson-Piercy, UK Supported by an unrestricted educational grant from Sanofi-Aventis |
|
|
15:45 |
Thromboprophylaxis after Cesarean Section: Decision Analysis Marc Blondon, Switzerland |
16:10 |
Diagnosis of Pulmonary Embolism in Pregnancy Menno V. Huisman, the Netherlands |
|
16:35 |
Pulmonary Hypertension in Pregnancy Franco Piovella, Italy |
|
17:00 |
Selected Oral Abstracts (2a) Efficacy of obstetric thromboprophylaxis and long-term risk of recurrence of (2b) Magnetic resonance imaging and ultrasonography in diagnosis of pelvic vein |
|
17:15-18:30 |
POSTER SESSION & Coffee Break |
|
20:00-22:00 |
Get Together Reception
|
|
Saturday, February 5, 2011 |
||
8:30-10:00 |
Session 3: BIOLOGIC BASIS OF HORMONAL EFFECTS ON
|
|
|
8:30 |
Mice Models of Obesity and Hormonal Therapy H. Roger Lijnen, Belgium |
8:55 |
Thrombin Generation Tests Elisabetta Castoldi, the Netherlands |
|
9:20 |
Haemostasis and Hormonal Contraceptives: Different Agents, Different Effects Jacqueline Conard, France |
|
9:45 |
Selected Oral Abstracts (3a) A microarray study on the effect of four hormone therapy regimens on gene (3b) SNPS in the SULT1E1 gene and the risk of oral contraceptive-associated venous |
|
10:00-10:30 |
Coffee Break & Exhibition Visit |
|
10:30-12:00 |
Session 4: HORMONAL THERAPY AND THROMBOSISChairmen: Paolo Simioni, Italy Emmanouil Papadakis, Greece |
|
|
10:30 |
Epidemiology of Hormonal Replacement Therapy and Thrombosis Pierre-Yves Scarabin, France |
10:55 |
Epidemiology of OCP and Thrombosis Phillip Hannaford, UK |
|
11:20 |
Controversies in Postpartum Contraception: When Is It Safe to Start OCP after Emily Jackson, Switzerland |
|
11:45 |
Selected Oral Abstracts (4a) Risk of VTE during combined oral contraceptive use and pregnancy in women with (4b) Effect of the dose of oral treatment with 17beta-estradiol associated with |
|
12:00 |
|
SATELLITE LUNCH SYMPOSIUM Sponsored by Sanofi-Aventis Novel Mechanisms - New Interventions Chairmen: Ian A Greer, UK and Benjamin Brenner, Israel |
|
|
Extended prophylaxis in medical patients S.M. Schellong, Germany Heparanase involvement in the placenta Yona Nadir, Israel Pregnancy complications as a risk factor to future vascular disease Ian A Greer, UK New anticoagulants: potential role in pregnancy? Ida Martinelli, Italy Anticoagulants for prevention of miscarriages and gestational vascular complications: Moderator: Benjamin Brenner Discussants: Marc Rodger, Jean-Christophe Gris, Saskia Middeldorp, Risto Kaaja |
14:00-15:55 |
Session 5: ANTIPHOSPHOLIPID SYNDROMEChairmen: Jacob H. Rand, USA Beatriz E. Grand, Argentina |
|
|
Biologic Basis of Disease in APS |
|
|
14:00 |
a. Mechanisms of APLA Formation Philip de Groot, the Netherlands |
14:25 |
b. Role of Complement in Gestational Complications Guillermina Girardi, USA |
|
|
APS – Controversies in Diagnosis and Management |
|
|
14:50 |
a. Unusual Clinical Presentations Mike Greaves, UK |
15:15 |
b. Critical Overview of Current Guidelines Vittorio Pengo, Italy |
|
15:40 |
Selected Oral Abstracts (5a) Antiphospholipid antibodies and the risk of intrauterine fetal death – Results of a (5b) Low molecular weight heparin actions on human endometrial angiogenesis; |
|
16:00-16:30 |
Coffee Break & Exhibition Visit |
|
16:30-18:00 |
Session 6: ARTERIAL THROMBOSISChairmen: Andra H. James, USA Silvia Hoirisch Clapauch, Brazil |
|
|
16:30 |
Vascular Complications in Diabetic Pregnancy Risto Kaaja, Finland |
16:55 |
Mechanical Heart Valves - Anticoagulation in Pregnancy Claire McLintock, New Zealand |
|
17:20 |
Resistance to Anti-Platelet Agents Marco Cattaneo, Italy |
|
17:45 |
Selected Oral Abstracts (6a) Nocturnal variability of coagulation in gestational diabetes; M. Pöyhönen-Alho, (6b) Role of protein S and tissue factor pathway inhibitor in the development of APC (6c) Oligoamenorrhea, high weight accrual rate, acanthosis and first trimester hypertriglyceridemia are independent predictors of preeclampsia; S. Hoirisch Clapauch, |
|
20:00 |
|
Farewell Dinner (Optional)
|
Sunday, February 6, 2011 |
||
8:30-10:30 |
Session 7: GESTATIONAL VASCULAR COMPLICATIONSChairmen: Simcha Yagel, Israel Gus Dekker, Australia |
|
|
8:30 |
Angiogenesis in Gestational Vascular Complications Simcha Yagel, Israel |
8:55 |
Microparticles and Pregnancy Complications Anat Aharon, Israel |
|
9:20 |
New insights into the aetiology of preeclampsia: identification of key elusive factors Asif Ahmed, UK |
|
9:45 |
LMWH for Prevention of Placental Insufficiency Marc Rodger, Canada |
|
10:10 |
Selected Oral Abstracts (7a) Enoxaparin for the secondary prevention of placental vascular complications in (7b) Low molecular weight heparin versus no treatment in women with previous |
|
10:30-11:00 |
Coffee Break & Exhibition Visit |
|
A.11:00-12:30(Potsdam I) |
Session 8: UNEXPLORED VENOUS THROMBOSIS IN WOMENChairmen: Ida Martinelli, Italy Rainer B. Zotz, Germany |
|
|
11:00 |
Superficial Thrombophlebitis Herve Decousus, France |
11:25 |
Venous Thrombosis at Unusual Sites Walter Ageno, Italy |
|
11:50 |
Postphlebitic Syndrome Susan R. Kahn, Canada |
|
12:15 |
Selected Oral Abstracts (8a) Prevalence and predictors for post-thrombotic syndrome (PTS) three to 16 years (8b) Reduced sensitivity to activated protein C in the absence of the factor V Leiden polymorphism is a risk factor for pregnancy related venous thrombosis; A. Bergrem, |
|
B. 11:00-12:30(Potsdam III) |
Session 9: PLACENTAL HEMOSTASISChairmen: Berend H. Isermann, Germany Michael Kupferminc, Israel |
|
|
11:00 |
Tissue Factor Expression on Decidual Cells Charles J. Lockwood, USA |
11:25 |
Is Placental Haemostasis Relevant to Recurrent IVF Failure? Scott Nelson, UK |
|
11:50 |
Placental Pathology in Pregnancy Complications Berthold Huppertz, Austria |
|
12:15 |
Selected Oral Abstracts (9a) Microparticles’ effect on apoptosis, angiogenesis and migration in healthy and (9b) p45NF-E2 epigenetically represses Gcm1 in trophoblast cells, regulating |
|
12:30-13:15 |
Lunch |
|
13:15-15:00 |
Session 10: HEPARINS IN PREGNANCYChairmen: Peter Clark, UK Pelle Lindqvist, Sweden Supported by an unrestricted educational grant from Sanofi-Aventis |
|
|
13:15 |
Biosimilar Heparin Derivatives Job Harenberg, Germany |
13:40 |
Monitoring of LMWH in Pregnancy: When and How Carl-Erik Dempfle, Germany |
|
|
LMWH Have No Place In Recurrent Pregnancy Loss: Debate |
|
|
14:05 |
|
14:25 |
|
|
14:45 |
Selected Oral Abstracts (10a) Risk of PPH in women using therapeutic dosage of LMWH during pregnancy (10b) Low-molecular-weight heparin for prevention of obstetric complications in |
|
15:00 -16:30 |
Session 11: BLEEDING IN WOMEN AND NEONATESChairmen: Rezan Abdul-Kadir, UK Ulrike Nowak-Göttl, Germany |
|
|
15:00 |
Antifibrinolytic Agents for Menorrhagia Claire S. Philipp, USA |
15:25 |
Post-Partum Hemorrhage in Women with Bleeding Disorders Flora Peyvandi, Italy |
|
15:50 |
Neonatal IVH - Mechanisms and Management Gili Kenet, Israel |
|
16:15 |
Selected Oral Abstracts (11a) Tranexamic acid reduces blood loss in post-partum haemorrhage; (11b) Gynaecological and obstetric bleeding in moderate and severe Von Willebrand |
|
16:30 |
Concluding Remarks - Symposium Chairmen |
|
|
Meeting Adjourned |